(Total Views: 459)
Posted On: 06/25/2024 5:51:51 PM
Post# of 148870
Here are summaries of several recent failures in cancer drug trials
June 25 (Reuters) - AstraZeneca's blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival in a late-stage trial in patients with a type of early-stage lung cancer, the group said on Tuesday.
Imfinzi is a human monoclonal antibody, which works to block a tumor's ability to evade and dampen the immune system, while also boosting the body's anti-cancer immune response, offering an alternative to chemotherapy.
https://www.reuters.com/business/healthcare-p...60a0256fed
June 24 (Reuters) - G1 Therapeutics said on Monday its drug for a rare, aggressive form of breast cancer did not meet the main goal of overall survival in a late-stage trial.
G1's drug trilaciclib was tested in 187 patients with metastatic triple-negative breast cancer, with the patients who took the drug showing a median overall survival of 17.4 months, while patients who did not receive the treatment survived for 17.8 months overall.
https://www.reuters.com/business/healthcare-p...60a0256fed
FRANKFURT, June 25 (Reuters) - Shares in Germany's Merck KGaA slumped 8.9% at the open on Tuesday after the diversified group late on Monday said a trial testing a head and neck cancer drug, previously seen as promising, would be stopped for lack of efficacy.
The failure of drug candidate xevinapant is the latest in a string of high-profile development setbacks, shifting the focus to the group's two other divisions, making specialty chemicals for the electronics industry as well as lab gear and supplies for the biotech sector.
https://www.reuters.com/business/healthcare-p...60a0256fed
June 25 (Reuters) - AstraZeneca's blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival in a late-stage trial in patients with a type of early-stage lung cancer, the group said on Tuesday.
Imfinzi is a human monoclonal antibody, which works to block a tumor's ability to evade and dampen the immune system, while also boosting the body's anti-cancer immune response, offering an alternative to chemotherapy.
https://www.reuters.com/business/healthcare-p...60a0256fed
June 24 (Reuters) - G1 Therapeutics said on Monday its drug for a rare, aggressive form of breast cancer did not meet the main goal of overall survival in a late-stage trial.
G1's drug trilaciclib was tested in 187 patients with metastatic triple-negative breast cancer, with the patients who took the drug showing a median overall survival of 17.4 months, while patients who did not receive the treatment survived for 17.8 months overall.
https://www.reuters.com/business/healthcare-p...60a0256fed
FRANKFURT, June 25 (Reuters) - Shares in Germany's Merck KGaA slumped 8.9% at the open on Tuesday after the diversified group late on Monday said a trial testing a head and neck cancer drug, previously seen as promising, would be stopped for lack of efficacy.
The failure of drug candidate xevinapant is the latest in a string of high-profile development setbacks, shifting the focus to the group's two other divisions, making specialty chemicals for the electronics industry as well as lab gear and supplies for the biotech sector.
https://www.reuters.com/business/healthcare-p...60a0256fed
(8)
(0)Scroll down for more posts ▼
